Langerhans cell histiocytosis is a rare histiocytic disorder. The disease is characterized by an abnormal accumulation of large numbers of pathologic Langerhans cells in the tissues, and is classified into unisystemic and multisystemic types depending on the number of systems involved.
1. Langerhans’ cell histiocytosis begins with pathologic Langerhans’ cells, and the specific etiology of the disease has not yet been clarified.
2. Clinical manifestations vary greatly from patient to patient. In mild cases, the disease is self-limiting; in severe cases, it may manifest as severe systemic multi-systemic lesions, which may be life-threatening. In children, the most common clinical manifestation is painful bone metastasis, and systemic symptoms such as fever and dyspnea may also occur.
3. The gold standard for the diagnosis of Langerhans’ cell histiocytosis is pathologic diagnosis.
4. Langerhans cell histiocytosis is mostly treated with chemotherapeutic drugs targeting myeloid tumors, such as cytarabine. The prognosis for adults is better than for children, and the prognosis for unisystemic lesions is better than for multisystemic lesions.
Diagnosis and treatment of specific diseases need to be under the supervision of a physician.